RMC-5552
- Generic Name
- RMC-5552
Revolution Medicines Doses First Patient in Phase 3 Trial of RMC-6236 for Metastatic Pancreatic Cancer
• Revolution Medicines initiated the Phase 3 RASolute 302 trial, evaluating RMC-6236 as monotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC).
• The global, randomized, open-label study will enroll approximately 460 patients who have previously received one line of therapy.
• RMC-6236 is an oral, direct RAS(ON) multi-selective inhibitor designed to suppress RAS signaling by blocking interaction with downstream effectors.
• The trial's primary endpoints are progression-free survival (PFS) and overall survival (OS) in patients with RAS mutations at position 12.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath